Janssen Pharma Applies for Bulk Controlled Substance Production
Published Date: 12/19/2025
Notice
Summary
Janssen Pharmaceuticals wants to make a lot of methylphenidate, a controlled drug used to treat conditions like ADHD. They’ve applied to get official permission to do this, and anyone who has concerns can speak up by February 17, 2026. This move affects drug makers and buyers and could impact the supply of this medicine.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Janssen Seeks Bulk Methylphenidate Registration
On November 7, 2025, Janssen Pharmaceuticals applied to be registered as a bulk manufacturer of methylphenidate (drug code 1724), listed as Schedule II. The application lists a manufacturing site at 1440 Olympic Drive, Athens, Georgia 30601-1645, and states the company plans to manufacture the substance for sale to its customers; no other activity is authorized for this registration.
Comment and Hearing Deadline: Feb 17, 2026
Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections, and may file a written request for a hearing, on or before February 17, 2026, via the Federal eRulemaking Portal at https://www.regulations.gov. Upon submission, commenters will receive a Comment Tracking Number.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-23466 — Importer of Controlled Substances Application: Groff Health Inc.
Groff Health Inc. wants to become an official importer of some powerful controlled substances like psilocybin and psilocyn. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 20, 2026. This move could shake up the market and rules around importing these substances, so keep an eye on the deadline!
Next: 2025-23468 — Importer of Controlled Substances Application: Bright Green Corporation
Bright Green Corporation wants to become an official importer of certain controlled substances like raw opium and poppy straw. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 20, 2026. This move could affect how these substances enter the U.S. and might impact businesses dealing with them.